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Abstract
Background: Endometriosis is a common benign condition, which is characterized by the growth of endometrial-
like tissue in ectopic sites outside the uterus. Laparoscopic excision of the disease is frequently carried out for the
treatment of severe endometriosis. Pelvic adhesions often develop following surgery and they can compromise the
success of treatment. Ovarian suspension (elevating both ovaries to the anterior abdominal wall using a Prolene
suture) is a simple procedure which has been used to facilitate ovarian retraction during surgery for severe pelvic
endometriosis. The study aims to assess the effect of temporary ovarian suspension following laparoscopic surgery
for severe pelvic endometriosis on the prevalence of post-operative ovarian adhesions.
Methods: A prospective double blind randomised controlled trial for patients with severe pelvic endometriosis
requiring extensive laparoscopic dissection with preservation of the uterus and ovaries. Severity of the disease and
eligibility for inclusion will be confirmed at surgery. Patients unable to provide written consent, inability to tolerate
a transvaginal ultrasound scan, unsuccessful surgeries or suffer complications leading to oophorectomies, bowel
injuries or open surgery will be excluded.
Both ovaries are routinely suspended to the anterior abdominal wall during surgery. At the end of the operation,
each participant will be randomised to having only one ovary suspended post-operatively. A new transabdominal
suture will be reinserted to act as a placebo. Both sutures will be cut 36 to 48 hours after surgery before the
woman is discharged home. Three months after surgery, all randomised patients will have a transvaginal
ultrasound scan to assess for ovarian mobility. Both the patients and the person performing the scan will be
blinded to the randomisation process.
The primary outcome is the prevalence of ovarian adhesions on ultrasound examination. Secondary outcomes are
the presence, intensity and site of post-operative pain.
Discussion: This controlled trial will provide evidence as to whether temporary ovarian suspension should be
included into the routine surgical treatment of women with severe pelvic endometriosis.
Trial registration: ISRCTN: ISRCTN24242218
Background
Endometriosis is a common benign condition, which is
characterized by the growth of endometrium-like tissue
in ectopic sites outside the uterus. The condition is a
significant cause of morbidity in women of the repro-
ductive age [1]. Symptoms of endometriosis include dys-
menorrhoea, dyspareunia, chronic pelvic pain and
subfertility. The revised American Society for Reproduc-
tive Medicine (ARSM) classification is the most widely
accepted staging system for endometriosis, where a
score is used to grade the disease as absent (0), minimal
(1-5), mild (6-15), moderate (16-40) or severe (> 40) [2].
Surgical excision of the disease is frequently carried out
for the treatment of severe endometriosis. Laparoscopic
approach to surgery provides superior views of the pelvis
and facilitates complete excision of endometriotic lesions
[3]. Although laparoscopic surgery is considered to be less
traumatic to pelvic tissues than open surgery, a significant
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even after this form of surgery. The most common site of
post-operative adhesions formation is the ovary [4]. For-
mation of severe post-operative adhesions can compro-
mise the success of surgery for endometriosis by causing
chronic pelvic pain, infertility, dysparaeunia and intestinal
obstruction [5]. Adhesions formation after laparoscopic
endometriosis surgery has been reported in the range of
50 to 100 percent [5-8].
The high incidence of post-operative adhesions in
endometriosis patients and their clinical significance
underlines the importance of modifying surgical techni-
ques in order to reduce potential adhesion formation.
Intra-peritoneal administration of anti-adhesive solutions
(e.g. icodextrin, hyaluronic acid) and drugs (e.g. steroids,
heparin) at the time of surgery has been advocated as a
way of reducing the incidence of post operative adhe-
sions. Currently, only anti-adhesive fluids containing hya-
l u r o n i ca c i dh a v es h o w e de v i d e n c eo fr e d u c t i o no f
adhesions however, more studies will be needed to con-
firm this [9]. Adjuvants have also been suggested to
further improve the adhesion reduction, however to date,
the most effective product for prevention of postopera-
tive adhesion is yet to be discovered [10].
Ovarian suspension
Ovarian suspension is a simple procedure which has been
used to facilitate ovarian retraction during surgery for
severe pelvic endometriosis without any reported compli-
cations [11]. A study by Abuzeid et al. showed that tem-
porary ovarian suspension following surgery for severe
endometriosis may lead to a reduction in post-operative
adhesions [12]. A small retrospective study also found
significant reductions in the number of women with
post-operative adhesions following ovarian suspension in
comparison with data from the literature [13].
Objective
The aim of this study is to assess the effect of temporary
o v a r i a ns u s p e n s i o nf o l l o w i ng laparoscopic surgery for
severe pelvic endometriosis on the prevalence of post-
operative ovarian adhesions.
Methods
This is a prospective double blind randomised con-
trolled trial which will be conducted at the University
College London Hospital Endometriosis Centre. This
centre is a tertiary referral unit for women with severe
pelvic endometriosis and receives patients from a wide
area of south east England.
Inclusion criteria
Women age 19 years or older who are diagnosed with
severe pelvic endometriosis on pre-operative transvaginal
ultrasound scan would be invited to join the study. Suit-
ability for randomisation will be determined at surgery.
Only women with severe endometriosis requiring exten-
sive dissection of both pelvic side walls and/or rectovagi-
nal space with preservation of the ovaries and uterus will
be included in the study.
Exclusion criteria are inability or unwillingness to pro-
vide written consent, inability to tolerate a transvaginal
ultrasound scan, unsuccessful surgeries and in cases of
complications such as unplanned oophorectomies,
bowel injuries or conversions to open surgery.
Interventions
During laparoscopic treatment for severe endometriosis,
both ovaries are routinely suspended to the anterior
abdominal wall using a Prolene suture, which is brought
out onto the skin and secured using a fine haemostat or
‘mosquito’ clip during surgery. This is performed to
facilitate access to the pelvic side walls during surgery
and a complete excision of the disease.
At the end of the operation, women will be randomised
to have one ovary suspended for 36 to 48 hours post-
operatively. One of the two ovarian suspension sutures
will be cut to allow that ovary to fall back into the lesser
pelvis. A new transabdominal suture will be reinserted at
the same site to act as a placebo. The pneumoperitoneum
will then be deflated and the Prolene stitch of the sus-
pended ovary will be tightened with a surgical knot placed
over the skin to secure the ovary to the abdominal wall.
This will ensure that the suspended ovary is lifted as far
away from the pelvis as possible. The surgical knots will
be secured with the space of a Carless scissor between the
skin and the knot to allow easier removal of the suture
and reduce patient discomfort. All randomized patients
will therefore have two abdominal sutures of similar length
and both the patient and clinical staff - apart from the sur-
gical team - will be blinded to the randomisation process.
A label will be attached to the operation notes to
define a) the randomisation number b) the operation
d a t ea n dt i m ea n dc )t h et i m et or e m o v et h es u t u r e s .
There will be no documentation of the randomisation
site in the operation notes.
B o t hs u t u r e sw i l lb ec u t3 6t o4 8h o u r sa f t e rs u r g e r y
b yaw a r dn u r s ew h ow i l ln o tb ep a r to ft h es t u d ya n d
will be blinded to the ovarian suspension site. The only
members of staff who will be aware of the site of ovar-
ian suspension will be the surgeons who will be under
strict instructions not to discuss individual patient’s
treatment allocations with the patient or any other
members of the clinical and nursing staff.
Randomisation
Participants will be randomised to unilateral suspension
of either the right or left ovary. Block randomisation
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size 4. The randomisation schedule will be produced by
our statistician using the external Stata command ralloc.
When a participant is recruited to the trial, consecu-
tive randomisation envelopes will be opened and the
principal surgeon will be told which ovary to suspend.
Only the patient’s randomisation number will be
recorded in the patient’s operation notes. No other
member of staff will be aware of women’s treatment
allocations.
At the end of the study, the randomisation will be
unblinded for analysis and details of the ovarian suspen-
sion will be added to each patient’s record.
Incident Reporting & unblinding procedure
A d v e r s ee v e n t sw i l lb er e c o r d e df r o mt h et i m eo fo v a r -
i a ns u s p e n s i o nu n t i lt h r e em o n t h sa f t e rs u r g e r yw h e n
the suspension results can be determined. The princi-
pal investigator will be responsible for the reporting of
all serious adverse events (SAE) or suspected unex-
pected serious adverse reactions (SUSAR) immediately
as the trial personnel become aware of an event to the
chief investigator. The chief investigator should report
all fatal or life-threatening events as soon as possible
to the joint biomedical research unit (JBRU). This
needs to be done not later than seven days after the
chief investigator was first aware of the reaction. All
events which are not fatal or life-threatening are also
reported as soon as possible and not later than 15 days
after the chief investigator was first aware of the reac-
tion. The research and ethics committee (REA) also
requires a report of all SAEs and SUSARs. The princi-
pal investigator will also follow all SAEs and SUSARs
through to outcome.
In cases where patients experience SUSAR, both sus-
pension sutures will be cut and the randomisation pro-
cess will be unblinded by contacting the principal
investigator or the ward sister who has a sealed rando-
misation envelope.
Ethical considerations
Approval for this study was o b t a i n e df r o mt h eM e d i c a l
Ethical Committees of the University College Hospital,
London, UK. In each patient fulfilling the inclusion cri-
teria, written informed consent is obtained before ran-
domisation. Women refusing participation are
registered.
Follow-up
Three months after ovarian suspension, all patients in
the study will be invited for a transvaginal ultrasound
scan to assess ovarian mobility (Figure 1). Ovarian
adhesions will be diagnosed in women with evidence
of restricted ovarian mobility on targeted palpation
using transvaginal ultrasound probe [14]. The
ultrasound operators will be blinded to the details of
the operative procedure and women’sr a n d o m i s a t i o n
allocation.
Outcome measures
Primary outcome measure The primary outcome is the
prevalence of ovarian adhesion on ultrasound after sur-
gery. The presence of ovarian adhesions will be assessed
by a combination of gentle pressure with the vaginal
probe and abdominal pressure with the examiners free
hand as in a bimanual examination. The presence of
ovarian adhesions will be diagnosed when the ovarian
mobility is restricted and the ovary cannot be separated
from the peritoneum of the lateral pelvic wall and/or
pouch of Douglas.
Secondary outcome measures Secondary outcomes are
the presence, intensity and site of post-operative pain.
Statistical analysis
Women with bilateral endometriosis will receive the
normal surgical treatment with the difference that one
ovary will be randomised to ovarian suspension and the
other to non-suspension. The primary outcome is the
binary variable of the presence of ovarian adhesions
three months after laparoscopic surgery. The data will
be paired binary data.
Figure 1 Flowchart of ovarian suspension study.
Hoo et al. BMC Women’s Health 2011, 11:14
http://www.biomedcentral.com/1472-6874/11/14
Page 3 of 5Pilot study
A pilot study was conducted to determine the preva-
lence of ovarian adhesion on transvaginal ultrasound
three months after routine laparoscopic treatment of
severe pelvic endometriosis (without ovarian
suspension).
Between 1st of March 2009 and 1st of September
2009, 16 women post laparoscopic treatment for severe
endometriosis were recruited. The mean age was 34.6
years (range 22 to 51). Histology confirmed the diagno-
sis of endometriosis in all 16 women. Post-operatively,
11/16 (68.8% 95% CI 46.0 to 91.5) women had evidence
of ovarian adhesions on TVS. 4/16 (25.0%, 95% CI 3.8
to 46.2) women had unilateral adhesions, while 7/16
(43.8%, 95% CI 19.4 to 68.1) women had adhesions
involving both ovaries. The ovarian adhesion rate for
each ovary was 18/32 (56.3%, 95% CI 39.1 to 73.4)
Sample size
The prevalence of ovarian adhesion for each ovary from
our pilot study was approximately 60% and this figure
was used to calculate the sample size. Clinically signifi-
cant improvement with ovarian suspension would be
defined as a 50% reduction in the prevalence of post-
operative ovarian adhesion.
The software provided by Machin et al. was used to
calculate the sample size [15]. Assuming two-sided 5%
significance and 80% power, 45 women would be
required for the study. This calculation assumes that the
response to suspension is independent to the response
to non-suspension. Allowing for a possible 10% dropout
during the follow up period, we plan to recruit 50
patients for the study.
Discussion
Ovarian adhesions after surgery for pelvic endometriosis
are common problems with its associated morbidity.
Numerous adhesion prevention strategies, mostly based
on microsurgical principles, have been reported. These
include minimalising tissue trauma, meticulous hemos-
tasis, irrigation and the use of low reactive sutures. Sus-
pending the ovaries post-operatively has been suggested
as an easy and possibly effective way of reducing ovarian
adhesions. To the best of our knowledge, a larger pro-
spective study has not been done to evaluate this. Our
randomised controlled trial will provide evidence as to
whether this simple surgical procedure should be
included into the routine surgical treatment of women
with severe pelvic endometriosis.
There is a potential risk of injury to the bowels and
blood vessels during insertion of the suspension sutures.
However, the chance of this occurring is likely to be very
small. There has also been no reported complication as a
result of ovarian suspension in previous studies.
The original study protocol was to perform a diagnos-
tic laparoscopy to assess for ovarian adhesions three
months after surgical treatment for endometriosis. How-
ever, due to problems with patient recruitment, the
study protocol was modified to the current study.
Traditionally, post-operative adhesions can only be
assessed by laparoscopy, but recent studies have shown
that targeted palpation with ultrasound probe could be
used as an alternative method to diagnose adhesion.
G u e r r i e r oe ta l .f o u n dt h a tt h ef i x a t i o no ft h eo v a r yt o
the uterus evaluated by transvaginal ultrasonography,
had a good specificity (86%) and high positive predictive
value (PPV) of 81% [16]. More recently, Okaro et al.
found good correlation between ovarian mobility on
transvaginal ultrasound and at laparoscopy (kappa 0.81)
[17]. These positive results were also shared by Holland
et al [14]. Transvaginal ultrasound has proven to be an
indispensible, non-invasive and inexpensive way of
assessing ovarian adhesion.
In our study, a decision was made to perform the
post-operative ovarian suspension for 36 to 48 hours.
This was different from the duration of suspension of 4
days by Ouahba et al [13]. Our decision was based on
an animal study by Harris et al. looking at the kinetics
of adhesion formation of injured peritoneal surfaces
[18]. They showed that a reduction of adhesion forma-
tion is achieved when separation of injured peritoneal
surfaces occurs for at least 36 hours. This was in accor-
dance with the duration of hospital stay after laparo-
scopic surgery for severe endometriosis. Therefore all
suspension stitches can be removed before surgical
discharge.
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